Healthcare

Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.

We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.

• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products

Healthcare Sub-Sectors

Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.

Healthcare Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has invested in
company name confidential

Latest Insights

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

Insights
27th July 2022

Transforming healthcare with real-world evidence (RWE)

The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]

Insights
23rd June 2022

BIO International in San Diego: Sunny with scattered economic clouds

The biopharma universe gathered in San Diego last week for the first face to face BIO International conference in three years. Turn-out was good but below the get-together in Philadelphia in 2019. That one topped out above 17,000 attendees according to the BIO website; whisper numbers this time around were in the region of 12,000. I […]